Although apoptosis may have originally evolved as a physiologic process, diverse pathologic processes are able to directly or indirectly activate the cell death mechanism. In the liver, apoptosis has been implicated in liver injury and hepatic failure from specific drugs and toxins, viral infection, autoimmune disorders, ischemia, allograft rejection, and sepsis (1) (2) (3) . TNF-␣, 1 interferon-␥, IL-1, and Fas have been shown to be important in hepatitis (1, 2) . The liver is very sensitive to Fas-mediated apoptosis. When mice are injected with anti-Fas antibody, the cause of death is secondary to liver failure (4) . In addition, FasϪ/Ϫ mice show hepatic hyperplasia, suggesting that the Fas pathway may be important for establishing liver structure (5) . Likewise, neutralizing antibodies against FasL or TNFR-1 receptors improve survival in hepatitis B virus surface antigen transgenic mice treated with hepatitis B virus surface antigenspecific cytotoxic lymphocytes (1) .
The potential hepatic anti-apoptotic role of IL-6, a known anti-apoptotic factor, was not known. However, it has been established that IL-6 has an important role in liver regeneration and repair from injury. IL-6Ϫ/Ϫ livers have impaired liver regeneration characterized by liver necrosis and failure, a blunted DNA response in hepatocytes, and discrete G 1 phase abnormalities including absence of STAT3 activation, and selective abnormalities in gene expression (6) that are corrected with pretreatment with IL-6. The acute liver injury noted in IL-6Ϫ/Ϫ livers following partial hepatectomy was not associated with increased hepatocyte apoptosis (6, 7) . IL-6 also ameliorates acute toxic liver injury (7) . Following a single dose of carbon tetrachloride (CCl 4 ), IL-6Ϫ/Ϫ livers developed increased hepatocellular injury and defective regeneration with significant blunting of STAT3 and NF-B activation and reduced hepatocyte DNA synthetic and mitotic responses. Increased hepatocyte apoptosis was also noted in IL-6Ϫ/Ϫ livers after CCl 4 treatment. Pretreatment with IL-6 prior to CCl 4 reduced CCl 4 -induced injury and apoptosis, and accelerated regeneration in both IL-6ϩ/ϩ and Ϫ/Ϫ livers (7) . However, the mechanism of IL-6 protection against CCl 4 -induced liver injury was unknown. CCl 4 is a hepatotoxin that causes direct hepatocyte injury by altering permeability of cellular, lysosomal, and mitochondrial membranes (8) . More significant is the indirect injury due to highly reactive free radicals formed from the metabolism of CCl 4 (8, 9) . Recently, it has been shown that CCl 4 causes not only primary liver necrosis but also hepatocyte apoptosis (10) . CCl 4 liver injury is associated with high levels of TNF-␣, which is felt to enhance injury and promote hepatocyte apoptotic death (11) .
The purpose of the current investigation was to determine if IL-6 exerts its protective effect on the liver at least in part through modulation of the apoptotic cell death program. Unlike CCl 4 , the binding of Fas ligand (FasL) or an agonistic antibody such as Jo-2 mAb to the Fas receptor directly causes hepatic injury by stimulating the apoptotic cell death program (4) . To demonstrate whether IL-6 can modulate liver injury that involved direct stimulation of hepatocyte apoptosis, IL-6Ϫ/Ϫ and ϩ/ϩ mice were treated with low levels of the Fas agonist Jo-2 mAb. In contrast to IL-6ϩ/ϩ mice, IL-6Ϫ/Ϫ mice developed lethal severe apoptotic hepatitis. Treatment with IL-6 prior to Jo-2 mAb improved survival in IL-6Ϫ/Ϫ mice and reduced injury in both IL-6Ϫ/Ϫ and ϩ/ϩ livers. The direct anti-apoptotic effects of IL-6 were demonstrated in vitro by its ability to decrease Fas-mediated apoptosis in both IL-6Ϫ/Ϫ and ϩ/ϩ primary hepatocyte cultures, and suggested that IL-6Ϫ/Ϫ hepatocytes had a pre-existing defect in apoptotic pathways. Several proximal and distal markers of apoptosis were elevated in IL-6Ϫ/Ϫ livers treated with Fas agonist. The finding of reduced levels of FLIP, Bcl-2, and Bcl-xL anti-apoptotic factors in IL-6Ϫ/Ϫ livers indicates that IL-6 acts at several points in the apoptotic pathway to protect the liver against cell death.
EXPERIMENTAL PROCEDURES
Animal Studies-Studies were performed on C57BL6/SV129 IL-6Ϫ/Ϫ and ϩ/ϩ mice 12-16 weeks of age. The IL-6 knockout mice were generated as described (12) . IL-6ϩ/ϩ and Ϫ/Ϫ colonies shared the same mixed C57BL6/SV129 background (back bred an additional generation onto C57BL6 from original C57BL6/SV129 mixture, thus 3/1 C57BL6/ SV129). Heterozygotes were back bred to maintain genetic similarity of the ϩ/ϩ and Ϫ/Ϫ colonies. The IL-6 genotype was confirmed in the breeders from each group by genomic DNA isolation and polymerase chain reaction as previously described (7) . IL-6Ϫ/Ϫ mice are developmentally normal and display abnormalities in the hepatic acute phase response, some immune mechanisms, and bone resorption in response to estrogen (4, (12) (13) (14) . Animals were maintained on an ad libitum diet of rodent laboratory chow 5008 (Ralston-Purina Co., St. Louis, MO). Mice were used with approval of IACUC and under National Institutes of Health guidelines.
The Fas Injury Model-In order to control for weight differences between mice, we injected 8 IL-6Ϫ/Ϫ and 8 IL-6ϩ/ϩ mice, an equal ratio of males and females ranging from 12 to 16 weeks old were injected intraperitoneally with 0.4 g/g weight of animal of the Fas agonist, Jo-2 mAb (PharMingen) following dilution to 100 l total volume with sterile normal saline (15, 16) . The average dose of Jo-2 mAb was 12.75 g for 8 IL-6Ϫ/Ϫ mice and 13.24 g for 8 IL-6ϩ/ϩ mice. The mice were monitored on the half-hour for 24 h and the time of death was recorded. Necropsy was performed after loss of heart beat and the cessation of respiration for 5 min in 3 IL-6Ϫ/Ϫ and 3 IL-6ϩ/ϩ animals. Liver, heart, lung, and kidney were harvested for H&E staining and TUNEL assay as described (7) . The dose of Fas agonist was then sequentially reduced to 0.15 g/g weight of Jo-2 mAb, the dose where initially, a number of IL-6ϩ/ϩ mice survived for 18 -24 h. Eight IL-6Ϫ/Ϫ and 8 IL-6ϩ/ϩ mice were given 0.15 g/g weight of Jo-2 mAb by sterile intraperitoneal injection following dilution to 100 l total volume with sterile normal saline. The IL-6Ϫ/Ϫ and IL-6ϩ/ϩ mice received an average dose of 4.44 and 4.64 g of Jo-2 mAb, respectively. The mice were monitored on the half-hour for 24 h and the time of death was recorded as above. Subsequently, IL-6Ϫ/Ϫ and ϩ/ϩ mice were injected intraperitoneally with 0.15 g/g Jo-2 mAb and livers were harvested for histology and TUNEL staining at 0, 3, 6, 12, and 18 h post-injection. For IL-6 treatment cohorts, mice were injected subcutaneously with human recombinant IL-6 (ϩIL-6) at 1 g/g wt (0.5% IL-6 solution in phosphate-buffered saline) (Gennaro Ciliberto) 20 min prior to 0.15 g/g weight intraperi- toneal injection of Jo-2 mAb and liver was harvested for histology and TUNEL staining at 0, 3, 6, 12, and 18 h post-injection. Four mice were studied at each time point in each cohort. Following IL-6 treatment, 8 IL-6ϩ/ϩ mice received 0.4 g/g Jo-2 mAb for an average dose of 12.86 mg and 8 IL-6Ϫ/Ϫ mice received 0.15 g/g Jo-2 mAb for an average dose of 4.46 g. The mice were monitored on the half-hour for 24 h and the time of death was recorded. There were no significant weight differences between IL-6Ϫ/Ϫ and ϩ/ϩ mice in any of the treatment cohorts studied. All treatment cohorts had an equal ratio of males and females ranging from 12 to 16 weeks old.
Four animals in each cohort were sacrificed at 0, 0.5, 1, 2, 3, 4, 6, and 12 h following treatment with 0.15 g/g Jo-2 mAb . Cohorts of IL-6Ϫ/Ϫ and ϩ/ϩ mice were also pretreated with a single subcutaneous injection of human recombinant IL-6 (ϩIL-6) at a dose of 1 g/g weight 20 min prior to 0.15 g/g Jo-2 mAb injection. Four animals in each IL-6 pretreated cohort were sacrificed at 0, 1, 2, 3, 4, 6, and 12 h. Four sham IL-6ϩ/ϩ controls received 100 l weight of sterile saline intraperitoneally and were sacrificed at 0, 0.5, 2, and 4 h. Under metophane anesthesia 200 l of blood was harvested from the right ventricle of the heart and the animal was then sacrificed by prompt total hepatectomy (7). The anterior two-thirds of the liver was processed for protein and/or RNA analysis and the posterior one-third of the liver was fixed in 10% neutral buffered formalin (Formalde-Fresh; Fisher Scientific, Fairlawn, NJ) (7, 17, 18) .
The formalin-fixed livers were then paraffin embedded in an automated tissue processor. 5-m liver sections were analyzed by H&E staining and immumohistochemistry (below). Serum was analyzed (Anilytics Inc., Gaithersburg, MD) for alanine and aspartate aminotransferase (ALT), total bilirubin, albumin, alkaline phosphatase, amylase, creatinine, glucose, cholesterol, and triglycerides (7) .
Hepatocyte Apoptosis-Four livers from each cohort were examined at 0-, 6-, 12-, and 18-h time points following 0.15 g/g weight intraperitoneally of Jo-2 mAb (PharMingen, San Diego, CA) % apoptotic hepatocytes. This was quantified by counting the average number of apoptotic hepatocytes per ϫ10 field of H&E stained IL-6Ϫ/Ϫ and ϩ/ϩ livers. Apoptosis was monitored histologically by scoring cellular condensation, hypereosinophilic cytoplasm, aggregation of basophilic chromatin at the nuclear membrane (pearl necklace appearance), condensation, and fragmentation of nuclear material into membrane bound vesicles (9, 11, 19, 20) . Ten fields per liver specimen were counted. The terminal deoxynucleotidyl transferase-mediated dUDP nick-end labeling (TUNEL) assay (Cell Death Detection Kit, Roche Molecular Biochemicals) was performed according to the manufacturer's recommendations and had excellent correlation with the H&E histologic data (7) .
Primary Hepatocyte Isolation-Primary mouse hepatoctyes were isolated using the two-step collagenase perfusion method adapted from Thorgeirsson and co-workers (21) . Under metofane anesthesia, the portal vein was exposed and canulated with a 25-gauge IV catheter secured to the portal vein by 4-0 surgical silk. The inferior vena cava was ligated and cut distal to ligature. The liver was perfused with a 37°C Hanks' balanced solution without calcium or magnesium containing 10 mM HEPES (Biofluids) and 0.2 mM EGTA (Sigma) for ϳ5 min. This was followed by perfusion with filter sterilized, 0.6 mg/ml solution of collagenase type 1 (Worthington Biochemical) in Williams buffer (glutamine-free Williams medium (Biofluids) with 10 mM HEPES at pH 7.4) for 5-10 min.
Viable hepatocytes (ϳ95%) were selected by isodensity centrifugation in Percoll and were resuspended in Dulbecco's modified Eagle's medium/F-12 media supplemented with 6.25 mg/ml transferrin, 1.25 mg/ml bovine serum albumin, 1 mg/ml galactose, 1 mM sodium pyruvate, 0.014 M sodium bicarbonate (Life Technologies, Inc.), 2 mM glutamine (BioWhitaker), 18 mM HEPES, and 10% fetal bovine serum (Hyclone). Viability was assessed with trypan blue exclusion. (22) 3 ϫ 10 6 hepatocytes were plated out per 35-mm plastic Petri dish containing a coverslip that was coated with rat tail collagen type 1 (Sigma) and incubated at 37°C in the presence of 0.5% CO 2 . Media was changed after 4 h attachment. Only hepatocyte cultures of 85-90% confluence and Ͼ95% viability were retained and placed in incubator for further study.
Hepatocyte Culture Sensitivity to Fas Agonist-Cultures were reexamined at 18 h to ensure Ͼ95% hepatocyte viability. IL-6Ϫ/Ϫ and ϩ/ϩ hepatocyte cultures were treated under differing conditions: 1) control; 2) 20 M MG132 (Biomol Research, Plymouth Meeting, PA), which inhibits NF-B activation by preventing IB degradation (22); 3) 1 g/ml Jo-2 mAb; 4) 20 M MG132 and 1 g/ml Jo-2 mAb; 5) 100 ng/ml IL-6; 6) 100 ng/ml IL-6 pretreatment followed by 20 M MG132; 7) 100 ng/ml IL-6 pretreatment followed by 1 g/ml Jo-2 mAb; 8) 100 ng/ml IL-6 pretreatment followed by 20 M MG132 and 1 g/ml Jo-2 mAb. IL-6 was given 1 h and MG132 30 min prior to Jo-2 mAb treatment. Two culture plates were studied for each condition per liver. Paired liver perfusions and cultures of IL-6Ϫ/Ϫ and IL-6ϩ/ϩ livers were performed on the same days. A total of 3 livers in each cohort were studied (6 plates/condition). After 5 h, the culture media was removed and cells were fixed with 2 ml of paraformaldehyde (3.6 gm in 100 ml of 1 ϫ phosphate-buffered saline) for 30 min then washed in 1 ϫ phosphatebuffered saline for 5 min. The terminal deoxynucleotidyl transferasemediated dUDP nick-end labeling (TUNEL) assay (Cell Death Detection Kit, Roche Molecular Biochemicals) was then performed.
Six slides were examined for each experiment and percent apoptosis was calculated for 5 random ϫ10 fields/slide. Mean percent apoptosis was calculated after counting the TUNEL positive brown nuclei (apo- Electrophoretic Mobility Shift Assay-Nuclear extracts from the anterior two-thirds of the livers were prepared as described (6) and stored at Ϫ70°C in 20 mM HEPES (pH 6.7), 0.2 mM EDTA, 100 mM KCl, 20% glycerol (v/v), 1.0 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride with protease inhibitors, 1 mM NaF, 1 mM Na 2 MoO 4 . All extracts were prepared in the presence of antipain, aprotinin, bestatin, and leupeptin (each at 2 mg/ml) (Roche Molecular Biochemicals, Indianapolis, IN). Protease inhibitors were added immediately at the time of harvest. Binding and supershift reactions for STAT3 and NF-B were performed essentially as described (6, 7). ␣-STAT3 primary antibody (Santa Cruz Biotechnology, Santa Cruz, CA) was used in the STAT3 supershift experiment.
Immunoblots-Preparation of whole liver cell extracts, protein electrophoresis, protein transfer, and protein detection was carried out as previously described (7, 22) . Primary antibodies used were Fas receptor, FADD, Bcl-2, Bcl-xL, caspase 3, Bax (Santa Cruz), ␤-actin (Sigma), BID (R & D Systems), FLIP, and caspase 8 (StressGen Biotechnologies, Canada) in a dilution of 1:1000. ␤-Actin protein expression was used to normalize protein loading for each blot. Secondary anti-mouse, antirabbit, or anti-goat horseradish peroxidase antibodies (Santa Cruz) were used in a dilution of 1:10,000. Protein expression was measured at 0, 2, 4, 6, and 12 h to note any differences between IL-6Ϫ/Ϫ and ϩ/ϩ livers. Significant time points were re-examined in triplicate with extracts from three livers for each treatment group. The immunoblot was scanned densitometrically to quantify protein levels (Image-Quant Software, Molecular Dynamics).
Immunofluorescent Detection of Cytochrome c-A mouse anti-cytochrome c monoclonal antibody (PharMingen), which solely recognizes the cytochrome c localized to the mitochondrial inner membrane but not cytochrome c released into the cytosol following Fas signaling was used to qualitatively demonstrate transduction of the Fas apoptotic pathway (23) . Formalin-fixed, parafin-embedded IL-6Ϫ/Ϫ, ϩ/ϩ, and Ϫ/Ϫ(ϩIL-6) liver sections were studied 0, 2, 4, 6, and 12 h following intraperitoneal injection with 0.15 g/g weight Jo-2 mAb (see above) for immunofluorescent mitochrondrial localization of cytochrome c with TSA-Direct (PerkinElmer Life Science) following the instructions of the manufacturer. Sections from three livers per cohort were examined at each time point. The cytochrome c primary antibody dilution was 1:250. The horseradish peroxidase-labeled anti-mouse secondary antibody was diluted to 1:1000. Slides were mounted with Vectashield (Vector Laboratories).
mRNA Analysis-For RNA preparation, anterior two-thirds of IL-6Ϫ/Ϫ, ϩ/ϩ, and Ϫ/Ϫ(ϩIL-6) livers were harvested, 3 livers per cohort per time point, and total liver RNA preparation was performed as described (6, 7) . Constitutive (time 0) mRNA expression of Bcl-xL, Bax, Bcl-2, and L32 (loading control) was assessed by the multiprobe ribonuclease protection assay, mAPO-2 Multi-Probe Template (PharMingen). FLIP mRNA expression was measured at 0 h for IL-6Ϫ/Ϫ and ϩ/ϩ livers by total liver RNA preparation, Northern blots, and hybridizations performed as described (6, 7) . ATP synthase was used as loading control. Full-length mouse FLIP cDNA was kindly provided by Dr. Jurg Tschopp (24) . The data was scanned densitometrically to quantify mRNA levels (Image-Quant Software, Molecular Dynamics). StatWorks (Apple Software, Cupertino, CA), Chi square test, and Student's t test were used for statistical analysis.
RESULTS

Decreased Survival and Increased Hepatocellular Apoptosis after Fas Agonist in IL-6Ϫ/Ϫ Mice, Corrected by IL-6 -IL-6
reduced hepatocyte necrosis and apoptosis following CCl 4 treatment. However, CCl 4 injury is multifactorial and is mediated by disruption of membrane permeability, TNF-␣, and the generation of toxic-free radicals (8, 9, 25) . To show whether IL-6 can prevent liver injury that involves direct stimulation of hepatocyte apoptosis, we injected IL-6Ϫ/Ϫ and ϩ/ϩ mice with a single, 0.4 g/g intraperitoneal dose of the Fas agonist, Jo-2 mAb. All IL-6Ϫ/Ϫ mice became lethargic and died rapidly (Fig.  1A) with an average time to death of 8 h. IL-6ϩ/ϩ mice appeared lethargic at 6 h and 7 subsequently died (Fig. 1A) with an average time to death of 10 h. There was one IL-6ϩ/ϩ survivor.
Although not significantly different, the data suggested that IL-6ϩ/ϩ mice had a slight survival advantage over IL-6Ϫ/Ϫ mice. The dose of Fas agonist was then reduced to 0.15 g/g where a distinction was observed in both survival and the degree of histologic liver injury between IL-6Ϫ/Ϫ and ϩ/ϩ mice. All 8/8 IL-6Ϫ/Ϫ mice died within 24 h and all 8/8 IL-6ϩ/ϩ mice survived (p Ͻ 0.001) (Fig. 1B) . IL-6Ϫ/Ϫ and ϩ/ϩ livers were then examined at various time points following treatment with 0.15 g/g Jo-2 mAb. Histologically, at 3 h, there was no evidence of hepatocyte apoptosis in either cohort. At 6 h, rare (Ͻ1%) apoptotic hepatocytes were noted in IL-6ϩ/ϩ livers ( Fig.  2A) . In contrast, at 6 h there was panlobular hepatocyte apoptosis in IL-6Ϫ/Ϫ livers with 45.5 Ϯ 4.8% apoptotic hepatocytes (p Ͻ 0.0001) (Fig. 2B ). These differences in apoptotic liver injury were supported by a Ͼ20-fold mean elevation in the ALT and a Ͼ10-fold mean elevation in the AST in IL-6Ϫ/Ϫ serum. The ALT and AST remained within normal limits in the IL-6ϩ/ϩ serum (p ϭ 0.02) (Fig. 3) . At 12 h, there was 33.6 Ϯ 6.2% apoptotic hepatocytes in IL-6ϩ/ϩ livers verses 91.6 Ϯ 5.1% apoptotic hepatocytes in IL-6Ϫ/Ϫ livers (p Ͻ 0.0001) (Fig. 2, C  and D) . The histologic examination of IL-6Ϫ/Ϫ livers revealed massive apoptotic injury, congestion, and parenchymal collapse. As a result of the massive hepatic congestion, sufficient blood was not obtained from right ventricular puncture in the IL-6Ϫ/Ϫ mice for serologic analysis. Elevations in the serum transaminases noted in the IL-6ϩ/ϩ serum at 12 h were similar to those noted in the IL-6Ϫ/Ϫ serum at 6 h. A mild inflam- To further demonstrate the protective effects of IL-6 in Fasmediated liver injury and death, 8 IL-6Ϫ/Ϫ mice were pretreated with a single dose of 1 g/g weight IL-6, 20 min prior to receiving a dose of 0.15 g/g weight of Jo-2 mAb. Seven IL-6Ϫ/ Ϫ(ϩIL-6) mice survived. One IL-6Ϫ/Ϫ(ϩIL-6) mouse died within 24 h (12.5% mortality) in contrast to the 100% 24 h mortality in IL-6Ϫ/Ϫ mice (p Ͻ 0.001) that did not receive IL-6 prior to Fas agonist (Fig. 1C) . IL-6Ϫ/Ϫ(ϩIL-6) livers were then examined at various time points following IL-6 and Jo-2 mAb treatment. At 6 h, the apoptotic injury was reduced to 3.1 Ϯ 1.3% (p Ͻ 0.0001). The mean AST level was reduced to within normal range (p Ͻ 0.4) and the mean ALT was reduced to a 2.8-fold elevation (Fig. 3) . At 12 h, IL-6Ϫ/Ϫ(ϩIL-6) livers had reduced apoptotic injury, with 34.6 Ϯ 7.6% apoptotic hepatocytes (p Ͻ 0.0001), compared with IL-6Ϫ/Ϫ livers (Fig. 2E) . Similarly at 12 h, wild-type livers pretreated with IL-6, IL-6ϩ/ ϩ(ϩIL-6), prior to 0.15 g/g weight of Jo-2 mAb had reduced apoptotic injury, with 15.5 Ϯ 6.6% apoptotic hepatocytes (p Ͻ 0.0001), compared with IL-6ϩ/ϩ livers (Fig. 2F) . Mean transaminases at 12 h were within normal range (p Ͻ 0.0001) (data not shown).
In order to note if IL-6 would improve the survival of IL-6ϩ/ϩ mice following a high dose Jo-2 mAb, 8 IL-6ϩ/ϩ mice pretreated with the single dose of IL-6 20 min prior to receiving 0.4 g/g weight Jo-2 mAb. Four IL-6ϩ/ϩ(ϩIL-6) mice survived.
Four IL-6ϩ/ϩ(ϩIL-6) mice died within 24 h (50% mortality) in contrast to the 87.5% 24 h mortality following the higher dose in IL-6ϩ/ϩ mice that did not receive IL-6 prior to Fas agonist (p Ͻ 0.005) (Fig. 1D) . There was no significant differences in either the weights of the animals or the amount of Jo-2 mAb that was given to any of the cohorts. These data suggest that IL-6 has a protective role against Fas-mediated apoptotic liver injury and death.
Increased Sensitivity to Fas-mediated Apoptosis in IL-6Ϫ/Ϫ Primary Hepatocytes-We investigated the role of IL-6 in Fasmediated hepatocyte apoptosis studies using IL-6Ϫ/Ϫ and ϩ/ϩ primary hepatocyte cultures. The IL-6Ϫ/Ϫ and ϩ/ϩ primary cultures, of hepatocytes used for these investigations had Ͼ95% viability. Apoptosis was not increased in untreated IL-6Ϫ/Ϫ hepatocytes compared with ϩ/ϩ primary hepatocyte controls (Ͻ1%). There was no increase in apoptosis following treatment with 1 g/ml Jo-2 mAb in either cohort. This is consistent with prior studies which demonstrate that wild-type primary cultured hepatocytes are resistant to death receptor-mediated apoptosis because of expressed NF-B (26) . This resistance may be overcome by blocking NF-B activation with agents such as MG132, which prevents IB degradation (27) . There was no difference in apoptosis from controls following treatment with MG-132 alone. However, treatment with 1 g/ml Jo-2 mAb and MG132 for 5 h increased apoptosis in IL-6Ϫ/Ϫ hepatocyte cultures (62.3 Ϯ 5.2%) compared with IL-6ϩ/ϩ cultures (7.8% Ϯ 2.5%) (p Ͻ 0.0001) (Fig. 4, A and B) . Pretreatment with 100 ng/ml IL-6 1 h prior to Jo-2 mAb/and MG132 reduced apoptosis in both IL-6Ϫ/Ϫ (14.1 Ϯ 4.2%) (p Ͻ 0.0001) (Fig. 4C) and ϩ/ϩ (3.1 Ϯ 1.4%) (p Ͻ 0.01) hepatocyte cultures. These data demonstrate an in vitro protective effect of IL-6 in Fas-mediated hepatocyte apoptosis, and suggest that IL-6Ϫ/Ϫ hepatocytes have an intrinsic defect in anti-apoptotic pathways.
STAT3 and NF-B Activation in IL-6Ϫ/Ϫ Livers Associated with Fas Ligation-STAT3
and NF-B activation following treatment with Fas agonist was studied to note if differences in their activation may explain the increased apoptosis noted in IL-6Ϫ/Ϫ livers. Both factors have been demonstrated to have anti-apoptotic effects (27) (28) (29) . Activation of STAT3 was dramatically increased in an IL-6-dependent manner post-hepatectomy and post-CCl 4 (7) . Unlike the models of injury in which peak STAT3 activation occurs at 2 h (7) STAT3 was detectable at only a low level at 2 h in the IL-6ϩ/ϩ livers following Fas agonist (Fig. 5A) . Moreover, STAT3 DNA binding activity at later time points (6 -12 h) was IL-6 independent and equal in IL-6ϩ/ϩ and Ϫ/Ϫ livers (Fig. 5A) , and was a measurement of liver regeneration and repair. NF-B levels also do not correlate with protection from Fas-mediated apoptosis. These data show that Fas agonist does not cause activation of IL-6-dependent pathways during the early time period in which IL-6 is protective against apoptosis.
Increased Activation of Both Proximal and Downstream Apoptotic Pathways in IL-6Ϫ/Ϫ Livers-Whole liver extracts
from IL-6Ϫ/Ϫ and ϩ/ϩ livers were used to examine the expression of the major proteins associated with the of Fas cell death signaling pathway. Differences in the protein expression of one or more components of the pathway could suggest a mechanism for the increased susceptibility of IL-6Ϫ/Ϫ hepatocytes to Fasmediated apoptosis.
Hepatic (0 h) expression of the major components of the death-inducing signaling complex the Fas receptor (FasR) and Fas-associated death domain (FADD) was the same in IL-6Ϫ/Ϫ and ϩ/ϩ livers (Fig. 6A ). There were no differences in FasR or FADD expression for up to 6 h post Jo-2 mAb. Expression at time zero of the "initiator" procaspase 8 (FLICE) and the "ex- A, FLIP RNA level was detected using Northern blot. There was no difference between IL-6ϩ/ϩ and Ϫ/Ϫ livers at 0 h. ATP synthase was used as a loading control. B, Bax, Bcl-2, and Bcl-xL mRNA level were analyzed using multiprobe ribonucleus protection assay. No differences were observed in constitutive levels of Bax, Bcl-2, and Bcl-xL mRNA. L32 is a loading control.
ecutioner" procaspase 3 were the same in IL-6Ϫ/Ϫ and ϩ/ϩ livers (Fig. 6B) . However, at 6 and 12 h post-Fas agonist at the 0.15 g/g dose, a 26,000 fragment cleaved from procaspase 8 and indicative of caspase 8 activation was noted only in the IL-6Ϫ/Ϫ livers (Fig. 6B) (23) . Similarly, evidence of procaspase 3 processing was noted only in the IL-6Ϫ/Ϫ livers. A 17,000 cleavage fragment of procaspase 3 was noted at 4 and 6 h post-Fas agonist as well as the active caspase 3 (12,000) at 6 and 12 h (Fig. 6B ). There were no differences in the constitutive expression of the pro-apoptotic factors Bid and Bax (Fig. 6C) . Loss of expression of both proteins were noted in the IL-6Ϫ/Ϫ livers at 6 and 12 h. Prior studies have shown that loss of expression of these factors following stimulation of the apoptotic pathway is indicative of caspase processing (30 -32) .
Loss of Cytochrome c Staining in IL-6Ϫ/Ϫ Hepatocytes PostFas Agonist-
The release of cytochrome c from the in mitochondrial membrane following caspase 8 activation is an important cofactor for caspase 3 activation (33) . Studies have shown that caspase-8 function is required for CD95-mediated cytochrome c release, effector caspase activation, and apoptosis and these responses were inhibited when caspase-8 was inhibited by FLIP (34) . A mouse anti-cytochrome c monoclonal antibody, which solely recognizes the cytochrome c localized to the mitochondrial inner membrane but not cytochrome c released into the cytosol was used to demonstrate differences in Fas signaling in IL-6Ϫ and ϩ/ϩ livers. Loss of cytochrome c signal precedes the appearance of the typical histologic features of apoptosis, thus loss of signal can be noted in histologically "intact" hepatocytes (23) . At 0 h and at 2 h following 0.15 g/g Jo-2 mAb, cytochrome c staining was present in all IL-6Ϫ/Ϫ and ϩ/ϩ hepatocytes (Fig. 7, A and B) . By 4 h, decreased signal was evident in numerous groups of 3-4 adjacent intact appearing hepatocytes in IL-6Ϫ/Ϫ livers only. At 6 h, there was no reduction in cytochrome c staining in IL-6ϩ/ϩ hepatocytes (Fig. 7C) . However, the IL-6Ϫ/Ϫ hepatocytes showed loss of cytochrome c staining in all apoptotic appearing hepatocytes and reduced or absent staining in virtually all of the remaining, hepatocytes (Fig. 7D ). Upon pretreating with IL-6, cytochrome c staining was preserved in Ͼ95% of IL-6Ϫ/Ϫ(ϩIL-6) hepatocytes at 6 h following Jo-2 mAb (Fig. 7E) . The inhibition of cytochrome c release in the IL-6ϩ/ϩ and IL-6Ϫ/Ϫ(ϩIL-6) hepatocytes suggests that IL-6 functions proximal to the mitochondria to block the transduction of the Fas stimulated death signal.
Decreased Protein Expression of Anti-apoptotic Proteins FLIP, Bcl-2, and Bcl-xL in IL-6Ϫ/Ϫ Livers-In order to see if susceptibility of IL-6Ϫ/Ϫ livers to Fas-induced apoptosis is due to abnormal expression of anti-apoptotic proteins, we examined the level of the apoptosis inhibitors at proximal and distal points in the Fas signaling pathway. Hepatic expression of FLIP protein, a dominant negative caspase 8, which potently inhibits the activation of caspase 8 (FLICE) proximal in the Fas apoptotic pathway (23, 33, 34) , was lower by 1.4-fold at time 0 but more remarkably decreased in IL-6Ϫ/Ϫ compared with IL-6ϩ/ϩ livers. After Fas agonist treatment, FLIP levels dropped rapidly in IL-6Ϫ/Ϫ livers but remained constant in IL-6ϩ/ϩ livers (Fig. 8A) . When three sets of samples from IL-6ϩ/ϩ and Ϫ/Ϫ livers at time 0 were compared, Bcl-2, an anti-apoptotic factor that acts at the level of the mitochondrial membrane (30, 32) , was reduced 7.4-fold (p ϭ 0.01) in IL-6Ϫ/Ϫ livers (Fig. 8, A and B) . Another anti-apoptotic protein, Bcl-xL, was reduced 3.0-fold (p ϭ 0.034) (Fig. 8, A and B) . After treatment with Fas agonist, IL-6Ϫ/Ϫ livers had reduced expression of both Bcl-2 and Bcl-xL at 2, 4, and 6 h (Fig. 8A) . In order to see if pretreatment with IL-6 before Fas agonist injection could prevent FLIP degradation in IL-6Ϫ/Ϫ livers, IL-6Ϫ/Ϫ mice were given a subcutaneous injection of IL-6 20 min before Fas agonist injection. FLIP protein remained constant in pretreated IL-6ϩ/ϩ and IL-6Ϫ/Ϫ livers up to 6 h post-Fas agonist injection (Fig. 8C) . However, IL-6 injection alone did not induce FLIP expression above the basal level within the short time frame, indicating that IL-6 might help maintain FLIP protein level by stabilizing the existing protein. Not only are FLIP protein levels less stable after Fas agonist treatment in IL-6Ϫ/Ϫ mice, IL-6Ϫ/Ϫ hepatocytes also have reduced FLIP stability. After 10 h treatment with Jo-2 mAb in the presence of the proteaosome inhibitor MG132, FLIP was largely degraded in the IL-6Ϫ/Ϫ hepatocytes but still present in the IL-6ϩ/ϩ hepatocytes. This finding again suggests that the apoptotic defect pre-exists in IL-6Ϫ/Ϫ hepatocytes.
Constitutive Transcription of Genes Associated with Fas Pathway-Differences in protein expression may be, in part, explained by differences in gene expression. Therefore we examined the expression of genes associated with the Fas-mediated apoptotic pathway. FLIP mRNA level in quiescent IL-6ϩ/ϩ and Ϫ/Ϫ livers were detected using Northern blot analysis. There were no significant differences in FLIP mRNA expression (Fig. 9A ). There were no differences in the expression of the genes that encode the pro-apoptotic protein Bax or the anti-apoptotic proteins Bcl-2 and Bcl-xL (Fig. 9B) , suggesting that levels of protein were regulated post-transcriptionally in the system.
DISCUSSION
Our previous studies have defined IL-6 as a critical proregenerative, anti-injury, and anti-fibrotic factor in the liver (6, 7) . IL-6Ϫ/Ϫ livers following partial hepatectomy developed increased necrotic injury, an absence of STAT3 activation, impaired early immediate gene activation, and impaired liver regeneration. Treatment with IL-6 reversed these abnormalities and normalized regeneration (6) . Likewise, IL-6Ϫ/Ϫ livers FIG. 10 . Model for IL-6 protection against Fas-mediated liver apoptosis. IL-6 may protect liver from apoptosis after Fas-agonist treatment by regulating several anti-apoptotic factors in the Fas signaling cascade. As shown in the model, when bound by its ligand, FasR associates into trimers and binds the adapter protein FADD (Muzio) . FADD can then bind, via a death effector domain, the zymogen form of caspase 8 (FLICE/MACH). Caspase 8 then oligomerizes and activates through self-cleavage. Caspase 8 is an initiator caspase and proximal in the apoptotic cascade (38) . If inactivated by FLIP (I-FLICE), the apoptotic signal will be terminated and the cell survives. IL-6 maintains FLIP protein level in the liver after Fas agonist treatment and prevents it from rapid degradation. Caspase 8 activates a complex and poorly understood process that culminates in mitochondrial membrane depolarization (mitochondrial permeability transition) and the translocation of cytochrome c from the inner mitochondrial membrane to the cytoplasm. Cytochrome c binds to Apaf-1 (apoptotic protease-activating factor-1), and in the presence of adenosine triphosphate, activates caspase 3. This executioner caspase cleaves intracellular substrates resulting in the characteristic morphologic and biochemical changes of apoptosis (39, 40) . Bcl-2 and Bcl-xL are anti-apoptotic proteins which function to maintain mitochondrial membrane integrity and prevent the release of cytochrome c. Bcl-xL has also been shown to inhibit the association of Apaf-1 to downstream caspases (41) . Likely through post-transcriptional mechanisms, IL-6 establishes an adequate level of Bcl-2 and Bcl-xL proteins in the liver cells to render them more resistance to Fas-mediated apoptosis.
subjected to a single dose of CCl 4 developed severe necrotic injury, increased hepatocyte apoptosis, and impaired regeneration. Treatment with IL-6 decreased liver injury and hepatocyte apoptosis and accelerated liver regeneration (7) . Finally, IL-6Ϫ/Ϫ livers, chronically dosed with CCl 4 , developed increased injury and fibrosis (7) . These data provide evidence for an important role for IL-6 in reducing acute and chronic liver injury and fibrosis (7) . However, the mechanism(s) through which IL-6 protects against liver injury were unknown.
The ability of IL-6 treatment to reduce CCl 4 -induced hepatocyte apoptosis suggested that at least one of the hepatoprotective mechanisms of IL-6 may be an ability to modulate pro-apoptotic stimuli (7). However, CCl 4 -induced liver injury is multifactorial and results in both liver necrosis and apoptosis. CCl 4 causes direct injury by altering hepatocyte membrane permeability (8) . CCl 4 also causes indirect injury due to the highly reactive free radicals formed from the metabolism of CCl 4 and through high levels of TNF-␣, which enhances injury and promotes hepatocyte apoptotic death (8 -10) . We utilized Fas ligation to note whether IL-6 exerts its protective effect on the liver at least in part through modulation of the apoptotic cell death program. Unlike CCl 4, the binding of Fas ligand (FasL) or an agonistic antibody such as Jo-2 mAb to the Fas receptor directly causes hepatic injury by activating the apoptotic cell death program (4) .
To demonstrate whether IL-6 can ameliorate liver injury that involves direct stimulation of an apoptotic pathway, IL-6Ϫ/Ϫ and ϩ/ϩ mice were treated with the Fas agonist, Jo-2 mAb. In contrast to IL-6ϩ/ϩ mice, IL-6Ϫ/Ϫ mice rapidly developed lethal severe apoptotic hepatitis. Treatment with IL-6 prior to Jo-2 mAb improved survival in IL-6Ϫ/Ϫ mice and reduced injury in both IL-6Ϫ/Ϫ and ϩ/ϩ livers. IL-6 pretreatment also improved survival in IL-6ϩ/ϩ mice using higher doses of Fas agonist. The anti-apoptotic effects of IL-6 were demonstrated in vitro by its ability to decrease Fas-mediated apoptosis in both IL-6Ϫ/Ϫ and ϩ/ϩ primary hepatocyte cultures and suggested that IL-6Ϫ/Ϫ hepatocytes had a pre-existing defect in apoptotic pathways. In IL-6ϩ/ϩ livers, these data also suggested that exogenous IL-6 can enhance protection in mice with an intact endogenous IL-6 response. When the Fas apoptotic pathway was examined in detail, a number of defects were found in IL-6Ϫ/Ϫ livers. Using similar doses of Fas agonist, the IL-6Ϫ/Ϫ livers had evidence of procaspase 8 processing, loss of mitochondrial cytochrome c, and procaspase 3 cleavage.
As shown in the model (Fig. 10) , our data suggest that IL-6 may function to maintain a critical level of these specific antiapoptotic factors within the hepatocytes. These anti-apoptotic factors allow the cells to maintain an appropriate threshold to prevent activation of a death program. The low threshold to apoptosis in IL-6Ϫ/Ϫ hepatocytes was associated with abnormal low levels and rapid degradation of the apoptosis inhibitors such as FLIP, Bcl-2, and Bcl-xL, indicating that IL-6 acts at several points in the apoptotic pathway to protect the liver against cell death.
A critical protective effect of IL-6 is likely the modulation of FLIP, the dominant negative inhibitor of caspase 8. As noted above, inactivation of caspase 8 terminates the Fas apoptotic pathway proximally, prior to mitochondrial depolarization and activation of the executioner caspases. FLIP has 2 death effector domains plus a caspase-like domain in which tyrosine substitutes for critical catalytic cysteine found in caspases. FLIP can be processed by caspase 8 and binds tightly to and inactivates caspase 8. FLIP also bind to FADD and procaspase 8 (FLICE) and inhibits apoptosis by all death receptors that require FADD and caspase 8 for signal transduction, including FAS, DR-3, DR-4, and TNFR-1. Resistance to Fas ligation has been shown previously to correlate with levels of FLIP protein expression in activated human T-cells, mouse splenocytes, melanoma, and cardiac myocytes (23, 35) . FLIP expression has also been noted to be increased in certain tumors, possibly offering a survival advantage (36) .
Several findings in this study suggested that the apoptotic defect pre-exists at least in part in IL-6Ϫ/Ϫ hepatocytes. There was rapid response in the IL-6Ϫ/Ϫ livers to Fas treatment without much de novo induction of STAT3 or NF-B. Preliminary gene expression array confirmed the lack of much transcriptional activation by Fas (data not shown). In addition, IL-6Ϫ/Ϫ primary hepatocytes were more susceptible to Fas, and there were reduced levels of anti-apoptotic factors Bcl-2 and Bcl-xL in quiescent IL-6Ϫ/Ϫ livers. Regulation appeared to be primarily post-transcriptional as little difference was observed in mRNA levels of FLIP, Bcl-2, and Bcl-xL. Furthermore, IL-6 also prevents these factors from being rapidly degraded after Fas agonist treatment. Although the mechanism of this regulation is unknown, IL-6 has a major role in regulating several protease inhibitors particularly the acute phase proteins. Many of these protease inhibitors act locally at the cellular level but there is no data to support their roles in anti-apoptosis (15, 37) .
In liver diseases that are shown to have increased hepatocyte apoptosis as a prominent component including both FasL-and TNF-␣-induced acute hepatitis, liver injury and failure (2, 3), treatment with IL-6 or stimulators of the IL-6 pathway may become a useful therapeutic option.
